Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302847 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 181
- Enrollment target
- 20
- Study locations
NCT01302847 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 181 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT01302847, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 181 participants
- Enrollment target
- 20
- Study locations
Study Summary
Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study evaluated the pharmacokinetics (PK), safety, tolerability of and immune response to DTG when used concurrently with optimized background therapy (OBT) in HIV-1 infected infants, children, and adolescents.
Conditions Studied
Interventions
- DRUG DTG film-coated tablets
- DRUG DTG granules for suspension
- DRUG DTG dispersible tablets
Study Locations (20)
California
- University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program (Site ID: 4601) - La Jolla
- Miller Children's Hosp. Long Beach CA NICHD CRS (Site ID: 5093) - Long Beach
- David Geffen School of Medicine at UCLA NICHD CRS (Site ID: 5112) - Los Angeles
- Univ. of California San Francisco NICHD CRS (Site ID: 5091) - San Francisco
New York
- Metropolitan Hosp. NICHD CRS (Site ID: 5003) - New York
- Bronx-Lebanon Hospital Center NICHD CRS (Site ID: 5114) - The Bronx
- Jacobi Med. Ctr. Bronx NICHD CRS (Site ID: 5013) - The Bronx
Florida
- South Florida CDTC Ft Lauderdale NICHD CRS (Site ID: 5055) - Fort Lauderdale
- USF - Tampa NICHD CRS (Site ID: 5018) - Tampa
Illinois
- Rush Univ. Cook County Hosp. Chicago NICHD CRS (Site ID: 5083) - Chicago
- Lurie Children's Hospital of Chicago (LCH) CRS (Site ID: 4001) - Chicago
Massachusetts
- Children's Hosp. of Boston NICHD CRS (Site ID: 5009) - Boston
- Boston Medical Center Ped. HIV Program NICHD CRS (Site ID: 5011) - Boston
Colorado
- Univ. of Colorado Denver NICHD CRS (Site ID: 5052) - Aurora
District of Columbia
- Howard Univ. Washington DC NICHD CRS (Site ID: 5044) - Washington D.C.
North Carolina
- DUMC Ped. CRS (Site ID: 4701) - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2011-04-20 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302847
The ClinicalTrials.gov registry entry for NCT01302847 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (59% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which DTG film-coated tablets is the first listed.
NCT01302847 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT01302847 about?
NCT01302847 is a clinical study titled "Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents". Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study evaluated the pharmacokinetics (PK), safety, tolerability of and immune response to DTG when used concurrently with optimized background therapy (OBT) in HIV-1 infected infants, children, and adolescents.
What is the current status of trial NCT01302847?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 181 participants. The study started on 2011-04-20. Estimated completion is 2023-10-18.
What conditions does trial NCT01302847 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT01302847?
The interventions under investigation include: DTG film-coated tablets (DRUG), DTG granules for suspension (DRUG), DTG dispersible tablets (DRUG).
Who is sponsoring clinical trial NCT01302847?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01302847 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.